Investment area
Seed Investments
Region
Europe
Date of investment
October 2023
LimmaTech Biologics AG is applying its deep expertise in engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases. Spun out from GlycoVaxyn after that company was acquired by GSK, LimmaTech Bio is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance and sexually transmitted infections such as gonorrhoea, alongside partnered programmes with GSK. LimmaTech is committed to translating novel scientific concepts into highly effective vaccines that benefit humanity.
Contact
Aleks Engel
Partner
Departments: Planetary Health Investments, Novo Holdings US Inc.
Aleks joined Novo Holdings A/S in 2014 and is Partner in the Planetary Health Investments team.
Aleks also leads Novo Holdings’ REPAIR Impact Fund targeting antimicrobial resistance.
Prior to joining Novo Holdings, Aleks was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).
Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.
